23-LUN-132-RBI-PMC: Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Grants and Contracts Details

StatusActive
Effective start/end date7/18/23 → 7/18/25

Funding

  • RayzeBio Incorporated: $70,301.00